3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Sarcoma
3
Sarcoma, Ewing
2
Insulin-Like Growth Factor I, Resistance To
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoid Tumor
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neuroendocrine Tumors
1
Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Jaundice
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Adenoma, Islet Cell
1
Adenocarcinoma
1
Interventions
Carboplatin
42
Etoposide
37
Cisplatin
23
Topotecan
22
Nivolumab
17
pembrolizumab
12
atezolizumab
12
Ipilimumab
10
Paclitaxel
9
durvalumab
8
Irinotecan
8
Radiosurgery
6
Pemetrexed
6
rovalpituzumab tesirine
5
Magnetic Resonance Spectroscopy
5
trioctyl phosphine oxide
4
trilaciclib
4
etoposide phosphate
4
berzosertib
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Dexamethasone
4
veliparib
3
tremelimumab
3
olaparib
3
carfilzomib
3
cabozantinib
3
Temozolomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Small Cell Lung Carcinoma
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts